Auro Laboratories Ltd

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Auro Laboratories Ltd has seen its investment rating downgraded from Buy to Hold as of 2 March 2026, reflecting a nuanced assessment across quality, valuation, financial trends, and technical indicators. Despite strong recent financial performance and impressive long-term returns, concerns over debt servicing ability and valuation metrics have tempered enthusiasm among analysts.

Auro Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 18 February 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Auro Laboratories Ltd has been upgraded from a Hold to a Buy rating by MarketsMOJO, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality. The pharmaceutical company’s recent quarterly results, robust price momentum, and consistent long-term returns have collectively driven this positive reassessment, signalling renewed investor confidence in its growth prospects.

Auro Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross—a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-DMA. This development signals a potential bullish breakout and a long-term momentum shift, suggesting renewed investor confidence and a possible trend reversal in the stock’s trajectory.

Auro Laboratories Ltd has reached a new 52-week and all-time high of Rs.317, reflecting a robust rally in the Pharmaceuticals & Biotechnology sector. This milestone underscores the stock’s strong momentum, outperforming its sector peers and the broader market over the past year.

Auro Laboratories Ltd has reached a significant milestone by hitting an all-time high in its stock price, reflecting a sustained period of strong performance within the Pharmaceuticals & Biotechnology sector. The stock’s recent surge underscores the company’s resilience and market strength as it outpaces key benchmarks and trading averages.

Auro Laboratories Ltd achieved a significant milestone on 12 Feb 2026, reaching a new 52-week high of Rs.308.9. This marks a notable peak in the stock’s performance, reflecting sustained momentum over the past year within the Pharmaceuticals & Biotechnology sector.

Auro Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.308.9 on 12 Feb 2026, underscoring a remarkable period of sustained growth and robust market performance.

Auro Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting significant improvements across financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s recent quarterly results and sustained market outperformance have driven this reassessment, signalling a more favourable outlook amid a challenging sector environment.

Auro Laboratories Ltd., a Mumbai-based generic Active Pharmaceutical Ingredients (API) manufacturer specialising in anti-diabetic compounds, reported a dramatic revenue recovery in Q2 FY26, with net sales surging 219.13% quarter-on-quarter to ₹8.84 crores. However, the micro-cap pharmaceutical company's consolidated net profit of ₹0.72 crores, whilst representing a turnaround from the previous quarter's loss of ₹0.11 crores, reflects an unusual tax rate of 58.14% that significantly compressed profitability. Following the results, the stock rallied 4.35% to ₹265.00 on February 5, 2026, though the company's market capitalisation remains modest at ₹156.00 crores.

Auro Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.